Stryker Raises Its Dividend Again - The Real Question Is Whether the Price Drop Gives You a Better Entry

Stryker raises its dividend to $0.88 per share for the second quarter of 2026 - technically a hold from the previous quarter, but the 4.8% annual increase marks the company's 15th consecutive year of dividend growth. The stock has fallen roughly 15% from its 52-week high, and the recent earnings report and cautious guidance have added to the pressure, with shares dropping 9% after hours. That's the setup that matters: the cash flow engine is humming, the payout is deeply covered, and the price is lower. If the income stream is still sound, a lower price is not a problem - it's the mechanism by which you buy more future income on better terms.

Let's look at what's actually producing the income.

Stryker makes medical devices - orthopedic implants, surgical robotics (the Mako platform, which passed 2.5 million procedures worldwide), and neurotechnology. Revenue comes from hospitals, surgeons, and health systems that buy equipment and consumables. The business is sticky: once a hospital installs Mako robotics or switches to Stryker implants, the switching cost is high. Q2 2026 organic sales grew 9%, with all three segments contributing. MedSurg and Neurotechnology grew 9.2% and orthopedics grew 8.6%. That's not a cyclical blip; it's broad-based demand from a $129 billion company selling into aging demographics and elective surgery recovery.

The payout is funded by operating cash flow, not accounting gymnastics. Stryker generated $5.5 billion in operating cash flow over the trailing twelve months and $4.7 billion in free cash flow after $823 million in capital expenditures. The annual dividend bill is roughly $1.35 billion (about 384 million shares times $3.52 per share). Free cash flow covers that dividend roughly 3.5 times. That's the kind of coverage ratio that makes "will they cut the dividend?" a hypothetical you can file under "extreme stress scenarios" rather than base cases.

The official trailing payout ratio sits at 49%, which already leaves substantial earnings retained for reinvestment, buybacks, and M&A. But the forward picture is even more comfortable. Stryker's full-year 2026 guidance calls for adjusted EPS of $14.95 to $15.10 - a midpoint of roughly $15.00. Against that, the $3.52 annual dividend implies a payout of about 23%. The disconnect between the 49% trailing ratio and the 23% forward ratio exists because Q1 2026 was dragged down by a cyberattack that disrupted manufacturing and ordering systems starting March 11. Adjusted EPS for Q1 came in at $2.60, well below the prior-year $2.84. The TTM denominator includes that weak quarter. As those results age out and the recovery quarters flow in, the trailing payout ratio will compress toward that 23% forward level. The dividend isn't just safe; it has room to grow even if earnings plateau.

Now to the part that's worrying people.

Stryker beat Q2 estimates - $3.69 adjusted EPS versus a $3.49 consensus on $6.6 billion in revenue - but then management narrowed full-year guidance rather than raising it. The new range calls for 8.3% to 9.3% organic growth, which is good but leaves little room for upside. Shares fell 9.2% in after-hours trading and have continued to drift, now sitting around $337 after a 52-week high near $397. The sell-off was also tinged with supply-chain anxiety: management said the Mako robotic platform had its best-ever second quarter for installations but that the company is still ramping production after the cyber disruption. Investors heard "we beat but the road ahead is tight."

That's a fair concern. A narrowed guidance band is a double-edged sword - it signals confidence but removes the option for a surprise upgrade. The second half of 2026 has to deliver the bulk of the guided growth after the Q1 disruption, and any execution stumble would pressure the stock further. But notice what the sell-off did not do: it did not break the cash-flow engine, widen the balance sheet, or threaten the dividend. Net debt sits at $11.5 billion against $24 billion in equity. The current ratio is 216%, meaning Stryker can meet short-term obligations more than twice over. Debt-to-equity is 62% - leveraged, but not dangerously so for a company generating $4.7 billion in free cash flow. The balance sheet is the kind that lets you survive a rough year without having to cut the payout to stay solvent.

The peer comparison reinforces the picture. Medtronic yields 3.3% and Abbott Laboratories yields 2.35%, both substantially higher than Stryker's roughly 1% yield. But Stryker trades at 35 times trailing earnings and 42 times forward earnings - among the most expensive of the group. You're not getting Stryker's income at a discount. At the same time, Stryker's 9% organic growth and 27.4% adjusted operating margin (up 170 basis points year over year) are better than what you'd expect from the lower-yielding peers at their valuations. Stryker is priced as a growth compounder that happens to pay a dividend, not as an income play. That matters because it means you're not buying it for the yield alone - you're buying the cash flow machine and accepting that the yield is modest until the price drops enough to push it up.

Here's the arithmetic that the income investor should file away. At Stryker's 52-week high near $397, the forward yield was roughly 0.89%. At the current price around $337, it's roughly 1.04%. That's not a screaming yield. But a 15% price decline on a company that just beat earnings, holds fortress-like free cash flow coverage of its dividend, and has 15 years of consecutive increases - that's the kind of move that rewards patient reinvestment. If you own 1,000 shares at $337, that's $337,000 of position and about $3,520 in annual income. If the price falls to $300 - which would push the yield toward 1.17% - the same $337,000 buys you 1,123 shares and roughly $3,953 in annual income. You're not waiting for the price to recover; you're buying more of the cash-flow stream on better terms.

What could break this thesis? A second-half execution miss that forces another guidance cut would be the most direct threat. Stryker narrowed its range precisely because management is confident, but if supply issues persist or Mako installations slow, that confidence evaporates. A broader healthcare sector pullback driven by policy or tariff uncertainty could also drag the stock further, compressing any near-term yield improvement. And the balance sheet, while healthy, is not bulletproof - $11.5 billion in net debt matters if operating cash flow were to fall sharply. The March cyberattack showed that operational risk is real, even if the payout was not affected.

But for the income investor, the action item is simpler. Stryker's dividend is intact, its free cash flow covers the payout more than three times, the forward payout ratio is a comfortable 23%, and the stock is down 15% from its high without any fundamental deterioration in the cash-flow engine. If the income stream is still sound, the lower price may simply mean you can buy more future income on better terms. This isn't a high-yield play - it's a durable-income compounder that's temporarily out of favor. Dollar-cost averaging into it, rather than waiting for a single bottom, is the move that turns the price weakness into portfolio yield.